Orchestra Biomed Holdings, Inc. (OBIO) — 10-Q Filings
All 10-Q filings from Orchestra Biomed Holdings, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Orchestra BioMed's Q3 Loss Widens Amid R&D Surge, Revenue Dip
— Nov 10, 2025 Risk: high
Orchestra BioMed Holdings, Inc. reported a net loss of $20.828 million for the three months ended September 30, 2025, an increase from $15.426 million in the sa -
Orchestra BioMed's Net Loss Widens 29% Amid Soaring R&D Costs
— Aug 12, 2025 Risk: high
Orchestra BioMed Holdings, Inc. (OBIO) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $38.118 million, up from $29 -
Orchestra BioMed Holdings Files 10-Q for Q1 2025
— May 12, 2025 Risk: medium
Orchestra BioMed Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Health Sciences Acquisitions Corp, reported financial -
Orchestra BioMed Files Q3 2024 10-Q
— Nov 12, 2024 Risk: medium
Orchestra BioMed Holdings, Inc. filed its quarterly report for the period ending September 30, 2024. The company, formerly known as Health Sciences Acquisitions -
Orchestra BioMed Holdings Files 10-Q
— Aug 12, 2024 Risk: low
Orchestra BioMed Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Health Sciences Acquisitions Corp 2, is incorporated i -
Orchestra BioMed Holdings, Inc. Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: medium
Orchestra BioMed Holdings, Inc. (OBIO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Orchestra BioMed Holdings, Inc. (OBIO) filed a 10-Q report
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX